Compare Adaptive Biotechnologies Corp (ADPT) vs Braze Inc (BRZE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Braze Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.03 (market cap $4.04B), while Braze Inc trades at $27.62 (market cap $3.18B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BRZE | |
|---|---|---|
Market Cap | $4.04B | $3.18B |
Sector | Health | Technology |
52-Week High | $25.45 | $36.19 |
52-Week Low | $12.30 | $15.79 |
Enterprise Value | $4.10B | $2.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Braze (BRZE) trades at $27.71, down 3.62% today, with strong analyst support (96% buy ratings) and a $34.78 consensus price target. The stock shows bullish technical momentum despite recent earnings misses, with revenue growing 30% year-over-year to $593M in 2025. Recent news highlights insider selling and AI-driven sector recovery, while the company maintains robust gross margins of 66.5% but remains unprofitable with a -15.5% net margin.
The outlook remains positive based on accelerating revenue growth and strong institutional backing, though profitability challenges and recent insider selling present near-term risks. With technical indicators showing bullish momentum and the stock trading below analyst targets, BRZE offers growth potential but requires monitoring of execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
